Want to see TSE:HEAL full AI Analyst Report?
Restart Life Sciences (HEAL) AI Stock Analysis
Top Page
Restart Life Sciences
(CNQX:HEAL)
The score is held down primarily by weak financial performance (no recurring revenue, ongoing losses, and persistent cash burn) and a bearish technical setup (price below key moving averages with negative MACD and oversold RSI). Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Restart Life Sciences (HEAL) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 519.02K
- Dividend Yield
- ―
- Average Volume (3M)
- 89.94K
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 0.49
- Revenue Growth
- ―
- EPS Growth
- -450.88%
- Country
- Canada
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Restart Life Sciences Business Overview & Revenue Model
Company Description
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder,...
Restart Life Sciences Financial Statement Overview
Summary
Overall financials are weak: revenue is effectively zero from 2021–2025 with persistent operating losses and negative operating/free cash flow (ongoing cash burn). The main offset is balance-sheet stabilization into 2025 (equity back to positive and relatively low debt), but funding dependence remains a key risk.
Income Statement
12Very NegativeBalance Sheet
38NegativeCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 465.71K | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -815.18K | 0 | 0 | 25.41K | -3,792 | -4,998 |
| EBITDA | -1.52M | -1.34M | -656.20K | -1.20M | -1.84M | -2.68M |
| Net Income | -1.50M | -1.39M | 224.75K | -1.22M | -3.76M | -2.68M |
Balance Sheet | ||||||
| Total Assets | 1.90M | 1.77M | 190.40K | 31.06K | 296.79K | 881.16K |
| Cash, Cash Equivalents and Short-Term Investments | 762.36K | 1.65M | 169.95K | 8,088 | 266.52K | 218.73K |
| Total Debt | 348.35K | 245.36K | 79.88K | 0 | 0 | 0 |
| Total Liabilities | 578.90K | 480.21K | 489.47K | 841.66K | 255.44K | 422.06K |
| Stockholders Equity | 1.32M | 1.29M | -299.07K | -810.60K | 41.34K | 459.10K |
Cash Flow | ||||||
| Free Cash Flow | -906.33K | -717.22K | -71.77K | -277.53K | -1.44M | -1.95M |
| Operating Cash Flow | -906.33K | -717.22K | -71.77K | -277.53K | -1.44M | -1.95M |
| Investing Cash Flow | -944.52K | 0 | 0 | 0 | 0 | 29.64K |
| Financing Cash Flow | 2.40M | 2.30M | 75.00K | 19.10K | 1.49M | 0 |
Restart Life Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEAL, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 61.86 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HEAL.
Restart Life Sciences Peers Comparison
Overall Rating
- TSE:HEAL42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:HEAL | 42Neutral | CAD 5.00M | -1.96 | -170.82% | ― | ― | -450.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:HEAL | Restart Life Sciences Corp. | 0.08 | -0.01 | -15.79% | |
| TSE:MYND | Mynd Life Sciences Inc | 0.07 | 0.00 | 0.00% | |
| TSE:IBO | Universal Ibogaine Inc | 0.01 | 0.00 | 0.00% | |
| TSE:MBIO | Mindbio Therapeutics Corp. | 0.10 | -1.90 | -94.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026